Alberto Parabiaghi

Dr. Alberto Parabiaghi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2011 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
APAlberto Parabiaghi
Alberto Parabiaghi
Carlotta FranchiCarlotta Franchi
Carlotta Franchi
MTMauro Tettamanti
Mauro Tettamanti
ABAngelo Barbato
Angelo Barbato
BDBarbara D’aVanzo
Barbara D’aVanzo
ANAlessandro Nobili
Alessandro Nobili

2 February 2015 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
APAlberto Parabiaghi
Alberto Parabiaghi
ABA. Barbato
A. Barbato
PRP. Risso
P. Risso
IFI. Fortino
I. Fortino
ABA. Bortolotti
A. Bortolotti
BDB. D’avanzo
B. D’avanzo
Introduction: Lithium is a highly specific and evidence-supported drug for the acute and maintenance treatment of bipolar disorder. Methods: The purpose of this study was to calculate the prevalence and incidence of lithium use and to investigate the prescribing patterns of other mood-stabilizing agents in lithium users. We analyzed lithium utilization from 2000 to 2010 in a large area in Italy on the basis of dispensing data drawn from the regional administrative database. For each calendar year those who had at least one recorded dispensation of lithium were defined as lithium users. Those who received more than 4 dispensations per year were defined as lithium-treated. Results: Rates of lithium utilization did not change during the observation period, but the amount of drug prescribed increased as a result of longer treatment and higher doses. The prevalence of use showed an initial increase of 8% (2000–2002), followed by a 13% decrease (2002–2006) and a subsequent rise of 11% (2006–2010). The prevalence of treatment grew by 38% during the whole observation period. The proportion of former lithium users who received other drugs or discontinued any treatment increased from 41% in 2002 to 52% in 2006, and then fell to 40% in 2010. Conclusion: The initial decline (2002–2006) and the subsequent rise (2006–2010) of lithium use can be explained by a fall and rise of new prescriptions. This finding together with a similar but opposite change in prescriptions of the other mood-stabilizing agents suggests a temporary change in prescribing attitudes which was subsequently reconsidered.

Verified
Journal Article
Open access
PDF file
APAlberto Parabiaghi
Alberto Parabiaghi
Matteo Monzio CompagnoniMatteo Monzio Compagnoni
Matteo Monzio Compagnoni
BDBarbara D’avanzo
Barbara D’avanzo
GCGiulia Caggiu
Giulia Caggiu
AGAlessia A. Galbussera
Alessia A. Galbussera
ABAngelo Barbato
Angelo Barbato
Background: Differences in survival between patients treated with antipsychotic monotherapy vs. polytherapy are debated. This study aimed to examine the association of antipsychotic polytherapy with 2-year all-cause mortality in a population-based cohort. Methods: Data were retrieved from healthcare databases of four local health units of Lombardy, Italy. Subjects aged 18–79 years who received continuous antipsychotic prescriptions in 2018 were identified. Overall survival among patients with antipsychotic monotherapy vs. polytherapy was compared. A multivariate Cox PH model was used to estimate the association between antipsychotic therapy, or antipsychotic use (continuous vs. non-continuous), and all-cause mortality. Adjustments were made for the presence of metabolic disturbances, total antipsychotic dosage amount (olanzapine equivalent doses), age, and sex. Results: A total of 49,875 subjects receiving at least one prescription of antipsychotics during 2018 were identified. Among the 33,221 patients receiving continuative antipsychotic prescriptions, 1958 (5.9%) experienced death from any cause at two years. Patients with continuous antipsychotic use had a 1.13-point increased mortality risk compared with non-continuous users. Patients treated with antipsychotic polytherapy showed an adjusted mortality risk increased by 17% (95% CI: 2%, 33%) compared to monotherapy. Conclusions: The study highlights the potential risks associated with antipsychotic polypharmacy, emphasizing the importance of optimizing drug prescriptions to improve patient safety and reduce mortality rates in individuals receiving antipsychotic therapy.

20 February 2024 in Early Intervention in Psychiatry
Verified
Journal Article
Open access
APAlberto Parabiaghi
Alberto Parabiaghi
ARAlessandro Alberto Rossi
Alessandro Alberto Rossi
ACAnna Castelnovo
Anna Castelnovo
LFLorenzo del Fabro
Lorenzo del Fabro
SMStefania Mannarini
Stefania Mannarini
FAfor the CCM2013 Project team (corporate authorship)
for the CCM2013 Project team (corporate authorship)
Background: Increasing attention to the early stages of psychosis and the identification of symptomatic prodromal states have led to the development of a growing number of screening tools. The 16‐item version of the Prodromal Questionnaire (PQ‐16) is a worldwide used self‐administered tool for this purpose. However, to date, fundamental psychometric properties of PQ‐16 were not thoroughly investigated. This study aimed to examine the structural validity, measurement invariance, reliability and other psychometrical properties of the Italian version of the PQ‐16 (iPQ‐16) in help‐seeking individuals and in the general population.Methods: The iPQ‐16 was administered to 449 young outpatients attending six community mental health services and to 318 control participants enrolled in educational environment. Confirmatory factor analyses (CFAs), measurement invariance (MI) between the help‐seeking group and the general population sample, convergent validity, test–retest reliability, internal consistency, and prevalence analyses were performed. Lastly, the validity of the adopted PQ‐16 cut‐offs through Receiver Operating Characteristic (ROC) curves plotted against CAARMS diagnoses was also tested.Results: CFAs confirmed the single‐factor structure for the iPQ‐16 and scalar MI was reached. The iPQ‐16 showed high internal consistency, test–retest reliability, convergent validity, and acceptable diagnostic accuracy. ROC analysis suggested a score of ≥4 as best cut‐off.Conclusions: The iPQ‐16 represents a valid and reliable questionnaire for the assessment of high mental risk in both Italian outpatients and general student population. It has good psychometric properties and is easy to implement as UHR screening for clinical as well as research purposes.